Table 2 Summary of tolerability data
From: Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
| Â | EZ/Simva 10/20 mg | Simva 40 mg | p-value |
|---|---|---|---|
Safety population n (%) | N = 102 | N = 111 | Â |
With adverse events | 18 (17.6) | 23 (20.7) | 0.606 |
With treatment-related adverse events | 10 (9.8) | 7 (6.3) | 0.500 |
Discontinued due to treatment-related adverse events | 1 (1.0) | 2 (1.8) | 0.999 |
Serious adverse events | 1 (0.1)* | 1 (0.1)†| 1.000 |
ALT/AST ≥ 3 × ULN | 0 | 0 | -- |
CK ≥ 5-10 × ULN | 0 | 0 | -- |